NCE-1 Intelligence & Market Opportunity

Palsonify

Paltusotine

Hormonal Therapy

Oral Tablet

Palsonify is an oral somatostatin receptor agonist approved for adults with acromegaly. It suppresses excess growth hormone and IGF-1 levels, providing a once-daily, non-injectable alternative to traditional therapies.

Approval Date

25-Sep-25

NCE-1 Date

25-Sep-29

NCE Date

25-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

2.2132

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

166

2028

327

2029

533

2030

782

2031

1040

2032

1286

Molecule profile

Details & specifications

Molecule

Paltusotine

Innovator

CRINETICS PHARMA INC

Dosage Form

Oral Tablet

Strength

20 mg and 30 mg

Therapeutic Category

Hormonal Therapy

Usage

To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.